<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Noncardiogenic pulmonary edema</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Noncardiogenic pulmonary edema</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Noncardiogenic pulmonary edema</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael M Givertz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary edema is due to the movement of excess fluid into the alveoli as a result of an alteration in one or more of Starling's forces. In cardiogenic pulmonary edema, a high pulmonary capillary pressure (as estimated clinically from the pulmonary artery wedge pressure) is responsible for the abnormal fluid movement [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/3487.html" rel="external">"Pathophysiology of cardiogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p>In contrast, noncardiogenic pulmonary edema is caused by various disorders in which factors other than elevated pulmonary capillary pressure are responsible for protein and fluid accumulation in the alveoli [<a href="#rid3">3</a>]. The distinction between cardiogenic and noncardiogenic causes is not always possible, since the clinical syndrome may represent a combination of several different disorders. The diagnosis is important, however, because treatment varies considerably depending upon the underlying pathophysiologic mechanisms.</p><p class="headingAnchor" id="H2"><span class="h1">THE STARLING RELATIONSHIP</span><span class="headingEndMark"> — </span>Fluid balance between the interstitium and vascular bed in the lung, as in other microcirculations, is determined by the Starling relationship, which predicts the net flow of liquid across a membrane. This can be expressed in the following equation:</p><div class="formulaContainer"><div class="formula"><p>Net filtration  =  (Lp x S)   x   (delta hydraulic pressure  -  delta oncotic pressure)</p></div></div><div class="formulaContainer"><div class="formula"><p>=   (Lp x S)   x   [(Pcap   -   Pif)   -  s(πcap   -   πif)]</p></div></div><p>where:</p><p class="bulletIndent1"><span class="glyph">●</span>Lp is the unit permeability (or porosity) of the capillary wall.</p><p class="bulletIndent1"><span class="glyph">●</span>S is the surface area available for fluid movement.</p><p class="bulletIndent1"><span class="glyph">●</span>Pcap and Pif are the capillary and interstitial fluid hydraulic pressures.</p><p class="bulletIndent1"><span class="glyph">●</span>πcap and πif are the capillary and interstitial fluid oncotic pressures; the interstitial oncotic pressure is derived primarily from filtered plasma proteins and to a lesser degree from proteoglycans in the interstitium.</p><p class="bulletIndent1"><span class="glyph">●</span>s represents the reflection coefficient of proteins across the capillary wall (with values ranging from 0 if completely permeable to 1 if completely impermeable).</p><p></p><p>In normal microvessels, there is ongoing filtration of a small amount of low protein liquid. In noncardiogenic pulmonary edema, the most common mechanism for a rise in transcapillary filtration is an increase in capillary permeability. At a given increase in capillary permeability, the rate of accumulation of lung liquid is related in part to the functional capacity of the lymphatic vessels to remove the excess fluid.</p><p class="headingAnchor" id="H3"><span class="h1">DEFINITION OF NONCARDIOGENIC PULMONARY EDEMA</span><span class="headingEndMark"> — </span>Noncardiogenic pulmonary edema is identified clinically by the presence of radiographic evidence of alveolar fluid accumulation without hemodynamic evidence to suggest a cardiogenic etiology (ie, pulmonary artery wedge pressure ≤18 mmHg). The accumulation of fluid and protein in the alveolar space leads to decreased diffusing capacity, hypoxemia, and shortness of breath.</p><p>The major causes of noncardiogenic pulmonary edema are the acute respiratory distress syndrome (ARDS) [<a href="#rid2">2</a>] and, less often, high altitude and neurogenic pulmonary edema. Other less common causes include pulmonary edema due to opioid overdose, pulmonary embolism, eclampsia, transfusion-related acute lung injury and acute kidney injury (sometimes referred to as “uremic lung”) [<a href="#rid4">4</a>]. Hypoalbuminemia alone is <strong>not</strong> a cause of pulmonary edema. (See <a class="local">'Absence of pulmonary edema with hypoalbuminemia'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">PERMEABILITY PULMONARY EDEMA DUE TO ARDS</span><span class="headingEndMark"> — </span>The alveolar-capillary membrane becomes damaged and leaky in cases of permeability pulmonary edema, allowing increased movement of water and proteins from the intravascular space to the interstitial space. In most patients, the concentration of protein in the interstitium exceeds 60 percent of the plasma value, compared to less than 45 percent in cardiogenic pulmonary edema [<a href="#rid5">5</a>].</p><p>Permeability pulmonary edema is the most prominent feature of acute respiratory distress syndrome (ARDS) [<a href="#rid6">6</a>]. In the past, many authors equated the clinical disorder ARDS with the pathological entity of permeability pulmonary edema. However, these two terms should <strong>not</strong> be used interchangeably. Although some degree of permeability edema is invariably present at the onset of ARDS, other important structural abnormalities of the lung typically emerge as ARDS evolves. Furthermore, many episodes of permeability pulmonary edema never result in the severe physiological impairment that is required for the designation ARDS. (See  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>.)</p><p>ARDS can be seen in a number of disorders, including sepsis, acute pulmonary infection, non-thoracic trauma, inhaled toxins, disseminated intravascular coagulation, shock lung, freebase cocaine smoking, postcoronary artery bypass grafting (especially in patients on <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>), inhalation of high oxygen concentrations, and acute radiation pneumonitis. Regardless of etiology, the clinical scenario is similar in most patients once membrane damage has occurred. Sepsis- or ischemia-induced release of cytokines, such as interleukin-1, interleukin-8, and tumor necrosis factor, may play an important role in the increase in pulmonary capillary permeability, at least in part via the recruitment of neutrophils [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Presentation and diagnosis</span><span class="headingEndMark"> — </span>Patients with ARDS present with severe respiratory distress (dyspnea) in association with the acute appearance of diffuse chest radiographic infiltrates and hypoxemia. The onset of ARDS is often within the first two hours after an inciting event, although this can be delayed as long as one to three days. Chest radiographs usually progress to a bilateral alveolar filling pattern. The diagnosis of permeability pulmonary edema requires distinction from cardiogenic pulmonary edema and from other causes of lung disease or injury.</p><p>Patients with noncardiogenic (or cardiogenic) pulmonary edema rarely have unilateral edema [<a href="#rid8">8-10</a>]. Unilateral noncardiogenic pulmonary edema may be caused by conditions ipsilateral to the edema such as aspiration, contusion, re-expansion, and pulmonary vein occlusion (eg, veno-occlusive disease or extrinsic compression) and by conditions contralateral to the edema such as pulmonary embolism and lobectomy [<a href="#rid8">8</a>]. These lesions should be distinguished from unilateral cardiogenic pulmonary edema, which is chiefly caused by eccentric mitral regurgitation [<a href="#rid11">11</a>] or following minimally invasive cardiac surgery [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Distinction from heart failure</span><span class="headingEndMark"> — </span>Clinically and radiographically, ARDS closely resembles severe cardiogenic pulmonary edema. The distinction between these disorders is often apparent from the clinical circumstances at the onset of respiratory distress. As examples, pulmonary edema occurring in the setting of an acute coronary syndrome is almost always cardiogenic, while that occurring in the setting of sepsis strongly suggests a noncardiac etiology. Pulmonary edema occurring in the setting of multiple transfusions could be due to a combination of cardiogenic pulmonary edema (eg, due to volume) and acute lung injury. (See  <a class="medical medical_review" href="/z/d/html/44.html" rel="external">"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary artery catheter – A pulmonary artery (or Swan-Ganz) catheter should be placed if the mechanism of edema formation cannot be discerned with confidence. A pulmonary artery wedge pressure less than 18 mmHg favors acute lung injury over cardiogenic pulmonary edema. (See  <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a>.)</p><p></p><p>It is important to appreciate that pulmonary artery catheterization can be misleading in certain settings. Most important, myocardial ischemia can cause severe but transient left ventricular dysfunction, leading to "flash" pulmonary edema. If the wedge pressure is first measured after the ischemia has resolved (and left ventricular function has improved), a relatively normal value may be obtained, leading to the erroneous conclusion that the respiratory distress was caused by acute lung injury. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p>On the other hand, an elevated pulmonary artery wedge pressure does not exclude the possibility of acute lung injury. It is estimated that as many as 20 percent of patients with ARDS have concomitant left ventricular dysfunction [<a href="#rid7">7</a>], and the percentages are much higher in patients with ARDS secondary to sepsis [<a href="#rid13">13</a>]. Right ventricular dilation is also commonly present in ARDS, while right ventricular dysfunction may be present in the most severe cases and predict worse outcomes [<a href="#rid14">14</a>]. The diagnosis of acute lung injury cannot be made easily when the wedge pressure is elevated; thus, the clinical course must be observed as the wedge pressure responds to treatment. If pulmonary infiltrates and hypoxemia do not improve appreciably within 24 to 48 hours after fluid restriction (with or without diuresis) and normalization of the wedge pressure, then acute lung injury probably coexists with cardiogenic edema.</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma BNP – Measurement of plasma B-type natriuretic peptide (BNP), or N-terminal pro-BNP, has been used to distinguish heart failure (high BNP) from lung disease (normal or mildly elevated BNP) as a cause of dyspnea with a high degree of accuracy even in patients with both lung and heart disease [<a href="#rid15">15</a>]. However, intermediate values are often not helpful. The role of these biomarkers in the diagnosis of pulmonary edema has been less well studied. Data in the ICU setting suggested limited ability to discriminate ARDS from cardiogenic pulmonary edema [<a href="#rid16">16</a>], as levels may increase with the development [<a href="#rid17">17</a>]and severity [<a href="#rid18">18</a>] of ARDS. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p></p><p>Clinical prediction tools have been developed to distinguish acute lung injury from cardiogenic pulmonary edema [<a href="#rid19">19</a>]. These may provide a guide to expediting initial therapy, but require further prospective evaluation. A number of novel biomarkers have also been proposed to aid in this distinction [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Other lung diseases</span><span class="headingEndMark"> — </span>Two pulmonary disorders are sometimes confused with ARDS: diffuse alveolar hemorrhage and cancer.</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse alveolar hemorrhage, often due to a pulmonary capillaritis or diffuse alveolar damage, should be considered whenever respiratory distress develops in association with a large, otherwise unexplained drop in the blood hemoglobin concentration. Hemoptysis may be minimal or absent prior to intubation; however, bronchoscopy after intubation invariably reveals bloody secretions throughout the airways during active hemorrhage.</p><p></p><p>Bland alveolar hemorrhage, which is characterized by hemorrhage into the alveolar spaces without inflammation or destruction of the alveolar structures, may be caused by elevated LV end diastolic pressure, coagulopathy, and, rarely, anticoagulant or antiplatelet therapy. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer sometimes disseminates throughout the lungs so rapidly that the ensuing respiratory failure may be mistaken for ARDS. This is most often due to lymphoma or acute leukemia [<a href="#rid21">21</a>], but lymphangitic spread of solid tumors, acute toxicity from chemotherapy (eg, <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a> [also known as Mitomycin-C], <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>), and cancer-associated DIC occasionally behave in a similar fashion [<a href="#rid22">22</a>]. Newer cancer treatments, including immune checkpoint inhibitors, have also been associated with pneumonitis [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>There are currently no known measures to correct the permeability abnormality in ARDS. Clinical management involves treatment of the underlying disease (eg, antibiotics for infection) and supportive measures to maintain cellular and metabolic function, while waiting for the acute lung injury to resolve. These supportive measures include mechanical ventilation, maintenance of adequate nutrition, and hemodynamic monitoring when necessary to guide fluid management and cardiovascular support [<a href="#rid24">24</a>]. Patients with severe ARDS may require extracorporeal membrane oxygenation in addition to supportive medical therapies [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a> and  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p>Lowering the pulmonary artery wedge pressure with diuretics and fluid restriction can improve pulmonary function and perhaps outcome [<a href="#rid26">26,27</a>]. One study, for example, analyzed survival and length of stay in the intensive care unit for 40 patients with ARDS [<a href="#rid26">26</a>]. The patients were divided into two groups: those with a reduction in pulmonary capillary wedge pressure (PCWP) of at least 25 percent; and those with less or no reduction in PCWP. Survival was greater in the patients with a large fall in PCWP (75 versus 29 percent). This difference remained statistically significant after stratifying patients by age and by the APACHE II severity of illness index. In a later study in which 1000 patients with acute lung injury were randomized to a conservative versus liberal fluid management strategy, the conservative strategy improved oxygenation and shortened duration of mechanical ventilation and ICU stay, but did not reduce the incidence of shock, use of dialysis or mortality during the first 60 days [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1655.html" rel="external">"Predictive scoring systems in the intensive care unit"</a>.)</p><p>A number of pharmacologic therapies for ARDS have been evaluated [<a href="#rid29">29</a>]. These include inhaled vasodilators (nitric oxide, prostacyclin), anti-inflammatory therapies (glucocorticoids, statins [<a href="#rid30">30</a>], prostaglandin E1), antioxidants (dietary oil supplementation), and exogenous surfactant. Novel mechanical ventilation strategies, including high-frequency ventilation, liquid ventilation, and prone positioning [<a href="#rid31">31</a>], as well as preventive strategies (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) [<a href="#rid32">32</a>] have also been investigated. At present, NONE has shown consistent and unequivocal clinical benefit [<a href="#rid33">33</a>]. Preclinical and early clinical data suggest that human mesenchymal stem cells may attenuate lung injury and promote tissue repair in ARDS. (See  <a class="medical medical_review" href="/z/d/html/1618.html" rel="external">"Acute respiratory distress syndrome: Investigational or ineffective therapies in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The outcome of patients with ARDS has improved over time; hospital mortality was approximately 60 percent in the years 1967 to 1981 and declined to 30 to 40 percent in the 1990s. As an example of this trend, one study evaluated 918 patients with ARDS at a single institution between 1983 and 1993 [<a href="#rid34">34</a>]. The mortality from sepsis-related ARDS declined from 67 percent in 1990 to 40 percent in 1993; the improvement was largely confined to patients under age 60. In a systematic analysis of ARDS studies published between 1994 and 2006, a decline in overall mortality rates of 1.1 percent per year was demonstrated [<a href="#rid35">35</a>]. The enhanced survival is probably related to a variety of improvements in supportive care. Despite these encouraging data, ARDS remains a world-wide problem with high mortality that is both under recognized and undertreated [<a href="#rid36">36</a>].</p><p>Most deaths are due to the severity of the underlying disease, particularly multiorgan failure, rather than the respiratory disease. While early deaths are typically due to the underlying cause of the ARDS, later deaths often result from nosocomial pneumonia and sepsis. Long-term survivors of ARDS typically show only mild abnormalities in pulmonary function and are usually asymptomatic, although long-term physical, cognitive, and psychological sequelae have been described [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/1601.html" rel="external">"Acute respiratory distress syndrome: Prognosis and outcomes in adults"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">OTHER NONCARDIOGENIC FORMS OF PULMONARY EDEMA</span><span class="headingEndMark"> — </span>Other more unusual types of noncardiogenic pulmonary edema, often with unclear pathophysiology, have been described.</p><p class="headingAnchor" id="H11"><span class="h2">High altitude pulmonary edema</span><span class="headingEndMark"> — </span>High-altitude pulmonary edema (HAPE), which generally occurs among individuals who rapidly ascend to altitudes above 12,000 to 13,000 feet (3600 to 3900 m), accounts for a majority of deaths due to high altitude disease [<a href="#rid39">39,40</a>]. An abnormally pronounced degree of hypoxic pulmonary vasoconstriction at a given altitude appears to underlie the pathogenesis of this disorder [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/181.html" rel="external">"High-altitude illness: Physiology, risk factors, and general prevention"</a> and  <a class="medical medical_review" href="/z/d/html/183.html" rel="external">"High-altitude pulmonary edema"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Neurogenic pulmonary edema</span><span class="headingEndMark"> — </span>Neurogenic pulmonary edema occurs after a variety of neurologic disorders and procedures, including head injury, intracranial surgery, grand mal seizures, subarachnoid or intracerebral hemorrhage, and electroconvulsive therapy [<a href="#rid41">41</a>]. Sympathetic overreactivity, with massive catecholamine surges, shifts blood from the systemic to the pulmonary circulation with secondary elevations of left atrial and pulmonary capillary pressures [<a href="#rid42">42</a>]. Pulmonary capillary leak caused by pressure-induced mechanical injury and/or direct nervous system control over capillary permeability may play a contributory role. The clinical presentation is characterized by acute hypoxemia, tachypnea, tachycardia, diffuse rales, and frothy sputum or hemoptysis. Symptom onset tends to be rapid and most cases resolve within 48 to 72 hours. The outcome is determined by the course of the primary neurologic insult. It is important to distinguish neurogenic pulmonary edema from cardiogenic pulmonary edema in the setting of stress cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/1610.html" rel="external">"Neurogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/z/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Reperfusion pulmonary edema</span><span class="headingEndMark"> — </span>Reperfusion pulmonary edema appears to represent a form of high-permeability lung injury that is limited to those areas of lung from which proximal thromboembolic obstructions have been removed. It may appear up to 72 hours after surgery and is highly variable in severity, ranging from a mild form of edema resulting in postoperative hypoxemia to an acute, hemorrhagic and fatal complication [<a href="#rid43">43-45</a>]. At experienced centers, venovenous extracorporeal life support has been used as a bridge to recovery or transplant when all other conventional strategies have failed [<a href="#rid46">46,47</a>] (see  <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy"</a>). A similar condition may occur following lung transplantation due to ischemia-reperfusion injury. (See  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Re-expansion pulmonary edema</span><span class="headingEndMark"> — </span>Re-expansion pulmonary edema (RPE) usually occurs unilaterally after rapid re-expansion of a collapsed lung (typically for greater than three days) in patients with a pneumothorax [<a href="#rid48">48</a>], with rates ranging from 16 to 33 percent. Risk factors include diabetes, size of pneumothorax, and presence of pleural effusion [<a href="#rid49">49,50</a>]. It may rarely follow evacuation of large volumes of pleural fluid (&gt;1 to 1.5 liters) (&lt;1 percent) [<a href="#rid51">51-54</a>] or removal of an obstructing endobronchial tumor.</p><p>The pathophysiologic mechanism is unknown. Proposed mechanisms include direct injury from surfactant dysfunction in chronic atelectatic lung, increased transpleural pressures when excessively negative pleural pressures are created during fluid or air removal in the setting of an unexpandable lung, or indirect injury from reperfusion.</p><p>RPE appears to be related to the rapidity of lung re-expansion and to the severity and duration of lung collapse. However, a study examining development of re-expansion pulmonary edema following thoracentesis found that it was independent of the volume of fluid removed and pleural pressures, and recommended that even large pleural effusions be drained completely as long as chest pain or end-expiratory pleural pressure less than -20 cm H<sub>2</sub>O does not develop [<a href="#rid53">53</a>].</p><p>Patients typically present soon (minutes to hours) after the inciting event, although presentation can be delayed for up to 24 to 48 hours in some cases. The clinical course varies from isolated radiographic changes to complete cardiopulmonary collapse but most patients present with acute onset dyspnea, cough and hypoxemia. Typical CT findings include ipsilateral ground-glass opacities, septal thickening, focal consolidation, and areas of atelectasis [<a href="#rid55">55</a>].</p><p>A mortality rate as high as 20 percent has been described in one small review [<a href="#rid56">56</a>]; however consistent with our experience, the mortality is much lower with later and larger series reporting a mortality rate less than 5 percent [<a href="#rid52">52,53,57</a>].</p><p>Treatment is supportive, mainly consisting of supplemental oxygen and, if necessary, mechanical ventilation. The disease is usually self-limited.</p><p class="headingAnchor" id="H15"><span class="h2">Opioid overdose</span><span class="headingEndMark"> — </span>First described by Osler in 1880 [<a href="#rid58">58</a>], pulmonary edema can sometimes complicate an overdose of heroin or <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> [<a href="#rid59">59</a>]; other related agents, including <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, have also been implicated [<a href="#rid60">60</a>]. Risk factors include male sex and shorter duration of heroin use. Most cases occur immediately or within hours of drug injection. The chest radiograph usually demonstrates a nonuniform distribution of pulmonary edema.</p><p>The pathophysiology of this form of pulmonary edema is unknown; a combination of direct toxicity of the drug, hypoxia, and acidosis secondary to hypoventilation and/or cerebral edema has been proposed [<a href="#rid61">61,62</a>]. The observation that edema fluid contains protein concentrations nearly identical to plasma and that pulmonary artery wedge pressures, when measured, are normal suggests an alveolar-capillary membrane leak as the initiating cause. Resolution of this form of pulmonary edema is rapid once hypoventilation and hypoxia are reversed by the institution of assisted ventilation. In one case series, 9 of 27 patients (33 percent) required mechanical ventilation; all but one were extubated within 24 hours [<a href="#rid63">63</a>]. Supportive care also includes use of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to reverse the opioid effects. The alarming increase in opioid use and dependency suggests that clinicians will see more cases of pulmonary edema related to opioid overdose in the emergency room and intensive care unit [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Salicylate toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> is one of many drugs occasionally associated with the development of noncardiogenic pulmonary edema. Salicylate-induced noncardiogenic pulmonary edema and acute lung injury (ALI) generally occur in older patients with chronic salicylate intoxication [<a href="#rid66">66,67</a>], but should be considered in all patients following aspirin overdose. The medical history is critical to making the diagnosis, as misdiagnosis or delayed diagnosis can lead to a significant increase in morbidity and mortality [<a href="#rid67">67</a>]. Salicylate-induced ALI and pulmonary edema can complicate volume resuscitation and administration of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, two mainstays of treatment in this setting. Thus, the presence of salicylate-induced pulmonary edema is considered an absolute indication for hemodialysis [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p class="headingAnchor" id="H949440151"><span class="h2">Other exogenous agents</span><span class="headingEndMark"> — </span>Several commonly-prescribed medications have been associated with noncardiogenic pulmonary edema, including <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) [<a href="#rid69">69,70</a>]. It may be difficult to distinguish noncardiogenic pulmonary edema from heart failure in cardiac patients or infection in immunosuppressed patients. Additional objective data, including invasive hemodynamics and tissue biopsy, may be helpful in these cases. Acute lung injury and death have also been reported with use of electronic cigarettes (vaping), and direct injury to lung epithelial cells with capillary leak has been proposed as a mechanism. (See  <a class="medical medical_review" href="/z/d/html/122671.html" rel="external">"E-cigarette or vaping product use-associated lung injury (EVALI)"</a> and  <a class="medical medical_review" href="/z/d/html/98400.html" rel="external">"Vaping and e-cigarettes"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Pulmonary embolism</span><span class="headingEndMark"> — </span>Acute pulmonary edema in association with a massive pulmonary embolus (PE) or multiple smaller emboli is uncommon but well described [<a href="#rid71">71,72</a>]. PE can cause pulmonary edema by injuring the pulmonary and adjacent pleural systemic circulations, elevating hydrostatic pressures in pulmonary and/or systemic veins, and perhaps by lowering pleural pressure due to atelectasis. PE may also decrease the exit rates of pleural fluid by increasing the systemic venous pressure (thereby hindering lymphatic drainage) or possibly by decreasing pleural pressure (thereby hindering lymphatic filling). The effusions are typically small and unilateral, and may become loculated if the diagnosis is delayed [<a href="#rid73">73</a>]. Older studies showed that 20 percent of PE-related effusions are transudates, suggesting that hydrostatic changes can also be important [<a href="#rid74">74</a>]. However, in a later case series, 26 of 93 patients with effusions following PE underwent thoracentesis and all of the fluids met Light's criteria for exudate (see  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>), suggesting a primary role for vascular injury [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Viral infections</span><span class="headingEndMark"> — </span>Rapidly progressive noncardiogenic pulmonary edema associated with profound hypotension and a high case fatality rate has been described with hantavirus infection (see  <a class="medical medical_review" href="/z/d/html/8321.html" rel="external">"Hantavirus cardiopulmonary syndrome"</a>) [<a href="#rid76">76</a>], dengue hemorrhagic fever/dengue shock syndrome (see  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>), and most recently with COVID-19 infection (see  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>). Enteroviral 71 infection in young children [<a href="#rid77">77</a>] and SARS coronavirus infection in adults [<a href="#rid78">78</a>] are other causes of viral-induced noncardiogenic pulmonary edema and hemorrhage (see  <a class="medical medical_review" href="/z/d/html/3027.html" rel="external">"Severe acute respiratory syndrome (SARS)"</a>). The strain of H1N1 influenza A that caused the 2009 to 2010 pandemic caused severe ARDS in some patients (see  <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>). There have also been reports of vascular leakage and respiratory failure in the setting of severe Ebola virus disease [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Pulmonary veno-occlusive disease</span><span class="headingEndMark"> — </span>Pulmonary veno-occlusive disease is a cause of pulmonary hypertension and noncardiogenic pulmonary edema. This condition is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8269.html" rel="external">"Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults"</a>.)</p><p class="headingAnchor" id="H4267783653"><span class="h2">Transfusion-related acute lung injury</span><span class="headingEndMark"> — </span>Transfusion-related acute lung injury (TRALI) is a rare but potentially fatal complication of blood product transfusion that involves neutrophil activation and pulmonary edema. Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">ABSENCE OF PULMONARY EDEMA WITH HYPOALBUMINEMIA</span><span class="headingEndMark"> — </span>In older patients with heart failure with preserved ejection fraction, hypoalbuminemia due to age, malnutrition, or sepsis may lower colloid osmotic pressure and facilitate the onset of pulmonary edema [<a href="#rid80">80</a>]. In patients with acute heart failure, hypoalbuminemia has also been associated with pleural effusions [<a href="#rid81">81</a>], and is an independent predictor of in-hospital and post-discharge mortality [<a href="#rid82">82</a>]. In a study of more than 7000 patients with acute coronary syndrome, serum albumin level ≤3.50 g/dL was an independent predictor of new-onset heart failure and in-hospital mortality [<a href="#rid83">83</a>].</p><p>Although hypoalbuminemia can lead to peripheral edema by lowering the transcapillary oncotic pressure gradient, it does not generally produce pulmonary edema. The pulmonary capillaries appear to have a greater baseline permeability to albumin and therefore have a higher interstitial oncotic pressure (about 18 mmHg) than do peripheral capillaries [<a href="#rid84">84</a>]. A fall in the plasma albumin concentration is associated with a parallel decline in the pulmonary interstitial oncotic pressure. The net effect is little or no change in the transcapillary oncotic pressure gradient and therefore no pulmonary edema, unless there is a concurrent rise in left atrial and pulmonary capillary pressures. (See  <a class="medical medical_review" href="/z/d/html/2309.html" rel="external">"Pathophysiology and etiology of edema in adults", section on 'Compensatory factors'</a>.)</p><p class="headingAnchor" id="H8052523"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Noncardiogenic pulmonary edema is caused by various disorders in which factors other than elevated pulmonary capillary pressure are responsible for protein and fluid accumulation in the alveoli. In contrast, a high pulmonary capillary pressure is responsible for the abnormal fluid movement in cardiogenic pulmonary edema. Noncardiogenic pulmonary edema may be difficult to distinguish from cardiogenic pulmonary edema and a mixed picture can occur. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Fluid balance between the interstitium and vascular bed in the lung, as in other microcirculations, is determined by the Starling relationship, which predicts the net flow of liquid across a membrane. In noncardiogenic pulmonary edema, the most common mechanism for a rise in transcapillary filtration is an increase in capillary permeability. Hypoalbuminemia alone is <strong>not</strong> a cause of pulmonary edema but can contribute to pleural effusions and increased mortality in patients with acute heart failure as well as in those with acute coronary syndrome. (See <a class="local">'The Starling relationship'</a> above and <a class="local">'Absence of pulmonary edema with hypoalbuminemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Noncardiogenic pulmonary edema is identified clinically by the presence of radiographic evidence of alveolar fluid accumulation without hemodynamic evidence to suggest a cardiogenic etiology (ie, pulmonary artery wedge pressure ≤18 mmHg). (See <a class="local">'Definition of noncardiogenic pulmonary edema'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiologies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common cause of noncardiogenic pulmonary edema is acute respiratory distress syndrome. (See <a class="local">'Permeability pulmonary edema due to ARDS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less common causes are high altitude and neurogenic pulmonary edema. (See <a class="local">'High altitude pulmonary edema'</a> above and <a class="local">'Neurogenic pulmonary edema'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Others include reperfusion and re-expansion pulmonary edema, heroin overdose or use of vaping products, and salicylate or other drug toxicity. (See <a class="local">'Reperfusion pulmonary edema'</a> above and <a class="local">'Re-expansion pulmonary edema'</a> above and <a class="local">'Opioid overdose'</a> above and <a class="local">'Salicylate toxicity'</a> above and <a class="local">'Other exogenous agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other less common causes include pulmonary edema due to pulmonary embolism and eclampsia, viral infections, pulmonary veno-occlusive disease, and transfusion-related acute lung injury. (See <a class="local">'Pulmonary embolism'</a> above and <a class="local">'Viral infections'</a> above and <a class="local">'Pulmonary veno-occlusive disease'</a> above and <a class="local">'Transfusion-related acute lung injury'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clark AL, Cleland JG. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol 2013; 10:156.</a></li><li><a class="nounderline abstract_t">Huppert LA, Matthay MA, Ware LB. Pathogenesis of Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med 2019; 40:31.</a></li><li><a class="nounderline abstract_t">Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.</a></li><li><a class="nounderline abstract_t">Scheel PJ, Liu M, Rabb H. Uremic lung: new insights into a forgotten condition. Kidney Int 2008; 74:849.</a></li><li><a class="nounderline abstract_t">Fein A, Grossman RF, Jones JG, et al. The value of edema fluid protein measurement in patients with pulmonary edema. Am J Med 1979; 67:32.</a></li><li><a class="nounderline abstract_t">Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334.</a></li><li><a class="nounderline abstract_t">Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:485.</a></li><li><a class="nounderline abstract_t">Kanner C, Hardy SM. An unusual cause of unilateral pulmonary edema. Ann Intern Med 2013; 158:639.</a></li><li><a class="nounderline abstract_t">Neerukonda SK, Petty TL. Unilateral pulmonary edema. Hosp Pract (Off Ed) 1992; 27:85, 88.</a></li><li><a class="nounderline abstract_t">Calenoff L, Kruglik GD, Woodruff A. Unilateral pulmonary edema. Radiology 1978; 126:19.</a></li><li><a class="nounderline abstract_t">Attias D, Mansencal N, Auvert B, et al. Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema. Circulation 2010; 122:1109.</a></li><li><a class="nounderline abstract_t">Kesävuori RI, Vento AE, Lundbom NMI, et al. Unilateral pulmonary oedema after minimally invasive and robotically assisted mitral valve surgery. Eur J Cardiothorac Surg 2020; 57:504.</a></li><li><a class="nounderline abstract_t">Jardin F, Fourme T, Page B, et al. Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 1999; 116:1354.</a></li><li><a class="nounderline abstract_t">Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest 2017; 151:181.</a></li><li><a class="nounderline abstract_t">Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39:202.</a></li><li><a class="nounderline abstract_t">Komiya K, Akaba T, Kozaki Y, et al. A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. Crit Care 2017; 21:228.</a></li><li><a class="nounderline abstract_t">Determann RM, Royakkers AA, Schaefers J, et al. Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients--relation to tidal volume size and development of acute respiratory distress syndrome. BMC Pulm Med 2013; 13:42.</a></li><li><a class="nounderline abstract_t">Sun YZ, Gao YL, Yu QX, et al. Assessment of acute lung injury/acute respiratory distress syndrome using B-type brain natriuretic peptide. J Int Med Res 2015; 43:802.</a></li><li><a class="nounderline abstract_t">Schmickl CN, Pannu S, Al-Qadi MO, et al. Decision support tool for differential diagnosis of Acute Respiratory Distress Syndrome (ARDS) vs Cardiogenic Pulmonary Edema (CPE): a prospective validation and meta-analysis. Crit Care 2014; 18:659.</a></li><li><a class="nounderline abstract_t">García-Laorden MI, Lorente JA, Flores C, et al. Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise. Ann Transl Med 2017; 5:283.</a></li><li><a class="nounderline abstract_t">Nanjappa S, Jeong DK, Muddaraju M, et al. Diffuse Alveolar Hemorrhage in Acute Myeloid Leukemia. Cancer Control 2016; 23:272.</a></li><li><a class="nounderline abstract_t">Federici AB, Intini D, Lattuada A, et al. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis. Thromb Res 2014; 133 Suppl 2:S56.</a></li><li><a class="nounderline abstract_t">Sears CR, Peikert T, Possick JD, et al. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2019; 200:e31.</a></li><li><a class="nounderline abstract_t">Cheng IW, Matthay MA. Acute lung injury and the acute respiratory distress syndrome. Crit Care Clin 2003; 19:693.</a></li><li><a class="nounderline abstract_t">Mi MY, Matthay MA, Morris AH. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med 2018; 379:884.</a></li><li><a class="nounderline abstract_t">Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990; 97:1176.</a></li><li><a class="nounderline abstract_t">Vignon P, Evrard B, Asfar P, et al. Fluid administration and monitoring in ARDS: which management? Intensive Care Med 2020; 46:2252.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564.</a></li><li><a class="nounderline abstract_t">Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 2019; 7:CD004477.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370:2191.</a></li><li><a class="nounderline abstract_t">Touchon F, Trigui Y, Prud'homme E, et al. Awake prone positioning for hypoxaemic respiratory failure: past, COVID-19 and perspectives. Eur Respir Rev 2021; 30.</a></li><li><a class="nounderline abstract_t">Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. JAMA 2016; 315:2406.</a></li><li><a class="nounderline abstract_t">Malhotra A, Drazen JM. High-frequency oscillatory ventilation on shaky ground. N Engl J Med 2013; 368:863.</a></li><li><a class="nounderline abstract_t">Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306.</a></li><li><a class="nounderline abstract_t">Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008; 133:1120.</a></li><li><a class="nounderline abstract_t">Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 2016; 315:788.</a></li><li><a class="nounderline abstract_t">Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364:1293.</a></li><li><a class="nounderline abstract_t">Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care 2019; 23:352.</a></li><li><a class="nounderline abstract_t">Bärtsch P, Swenson ER. Clinical practice: Acute high-altitude illnesses. N Engl J Med 2013; 368:2294.</a></li><li><a class="nounderline abstract_t">Luks AM, Swenson ER, Bärtsch P. Acute high-altitude sickness. Eur Respir Rev 2017; 26.</a></li><li><a class="nounderline abstract_t">Finsterer J. Neurological Perspectives of Neurogenic Pulmonary Edema. Eur Neurol 2019; 81:94.</a></li><li><a class="nounderline abstract_t">Busl KM, Bleck TP. Neurogenic Pulmonary Edema. Crit Care Med 2015; 43:1710.</a></li><li><a class="nounderline abstract_t">Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141:702.</a></li><li><a class="nounderline abstract_t">Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.</a></li><li><a class="nounderline abstract_t">Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. J Am Coll Cardiol 2020; 76:2155.</a></li><li><a class="nounderline abstract_t">Boulate D, Mercier O, Mussot S, et al. Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients. Ann Thorac Surg 2016; 102:260.</a></li><li><a class="nounderline abstract_t">Martin-Suarez S, Gliozzi G, Fiorentino M, et al. Role and management of extracorporeal life support after surgery of chronic thromboembolic pulmonary hypertension. Ann Cardiothorac Surg 2019; 8:84.</a></li><li><a class="nounderline abstract_t">Sohara Y. Reexpansion pulmonary edema. Ann Thorac Cardiovasc Surg 2008; 14:205.</a></li><li><a class="nounderline abstract_t">Yoon JS, Suh JH, Choi SY, et al. Risk factors for the development of reexpansion pulmonary edema in patients with spontaneous pneumothorax. J Cardiothorac Surg 2013; 8:164.</a></li><li><a class="nounderline abstract_t">Taira N, Kawabata T, Ichi T, et al. An analysis of and new risk factors for reexpansion pulmonary edema following spontaneous pneumothorax. J Thorac Dis 2014; 6:1187.</a></li><li><a class="nounderline abstract_t">Mynarek G, Brabrand K, Jakobsen JA, Kolbenstvedt A. Complications following ultrasound-guided thoracocentesis. Acta Radiol 2004; 45:519.</a></li><li><a class="nounderline abstract_t">Jones PW, Moyers JP, Rogers JT, et al. Ultrasound-guided thoracentesis: is it a safer method? Chest 2003; 123:418.</a></li><li><a class="nounderline abstract_t">Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84:1656.</a></li><li><a class="nounderline abstract_t">Lin YJ, Yu YH. Reexpansion pulmonary edema after large-volume thoracentesis. Ann Thorac Surg 2011; 92:1550.</a></li><li><a class="nounderline abstract_t">Gleeson T, Thiessen R, Müller N. Reexpansion pulmonary edema: computed tomography findings in 22 patients. J Thorac Imaging 2011; 26:36.</a></li><li><a class="nounderline abstract_t">Sherman SC. Reexpansion pulmonary edema: a case report and review of the current literature. J Emerg Med 2003; 24:23.</a></li><li><a class="nounderline abstract_t">Sagar AES, Landaeta MF, Adrianza AM, et al. Complications following symptom-limited thoracentesis using suction. Eur Respir J 2020; 56.</a></li><li class="breakAll">Osler W. Oedema of the left lung—morphia poisoning. Montreal General Hospital Reports Clinical and Pathological, vol 1, Dawson Bros Publishers, Montreal 1880. p.291.</li><li><a class="nounderline abstract_t">Dezfulian C, Orkin AM, Maron BA, et al. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. Circulation 2021; 143:e836.</a></li><li><a class="nounderline abstract_t">Farkas A, Lynch MJ, Westover R, et al. Pulmonary Complications of Opioid Overdose Treated With Naloxone. Ann Emerg Med 2020; 75:39.</a></li><li><a class="nounderline abstract_t">Radke JB, Owen KP, Sutter ME, et al. The effects of opioids on the lung. Clin Rev Allergy Immunol 2014; 46:54.</a></li><li><a class="nounderline abstract_t">Dettmeyer R, Schmidt P, Musshoff F, et al. Pulmonary edema in fatal heroin overdose: immunohistological investigations with IgE, collagen IV and laminin - no increase of defects of alveolar-capillary membranes. Forensic Sci Int 2000; 110:87.</a></li><li><a class="nounderline abstract_t">Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema : a case series. Chest 2001; 120:1628.</a></li><li><a class="nounderline abstract_t">Cobaugh DJ, Gainor C, Gaston CL, et al. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm 2014; 71:1539.</a></li><li><a class="nounderline abstract_t">Winklhofer S, Surer E, Ampanozi G, et al. Post-mortem whole body computed tomography of opioid (heroin and methadone) fatalities: frequent findings and comparison to autopsy. Eur Radiol 2014; 24:1276.</a></li><li><a class="nounderline abstract_t">Heffner JE, Sahn SA. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann Intern Med 1981; 95:405.</a></li><li><a class="nounderline abstract_t">Glisson JK, Vesa TS, Bowling MR. Current management of salicylate-induced pulmonary edema. South Med J 2011; 104:225.</a></li><li><a class="nounderline abstract_t">Papacostas MF, Hoge M, Baum M, Davila SZ. Use of continuous renal replacement therapy in salicylate toxicity: A case report and review of the literature. Heart Lung 2016; 45:460.</a></li><li><a class="nounderline abstract_t">Almeida F, Amorim S, Sarmento A, Santos L. Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature. Transplant Proc 2018; 50:933.</a></li><li><a class="nounderline abstract_t">Wang WL, Yu LX. Acute respiratory distress attributed to sirolimus in solid organ transplant recipients. Am J Emerg Med 2015; 33:124.e1.</a></li><li><a class="nounderline abstract_t">Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010; 363:266.</a></li><li><a class="nounderline abstract_t">Jaber WA, Fong PP, Weisz G, et al. Acute Pulmonary Embolism: With an Emphasis on an Interventional Approach. J Am Coll Cardiol 2016; 67:991.</a></li><li><a class="nounderline abstract_t">Porcel JM, Light RW. Pleural effusions due to pulmonary embolism. Curr Opin Pulm Med 2008; 14:337.</a></li><li><a class="nounderline abstract_t">Brown SE, Light RW. Pleural effusion associated with pulmonary embolization. Clin Chest Med 1985; 6:77.</a></li><li><a class="nounderline abstract_t">Porcel JM, Madroñero AB, Pardina M, et al. Analysis of pleural effusions in acute pulmonary embolism: radiological and pleural fluid data from 230 patients. Respirology 2007; 12:234.</a></li><li><a class="nounderline abstract_t">Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis 2002; 34:1224.</a></li><li><a class="nounderline abstract_t">Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929.</a></li><li><a class="nounderline abstract_t">Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953.</a></li><li><a class="nounderline abstract_t">Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 2015; 385:1428.</a></li><li><a class="nounderline abstract_t">Arquès S, Ambrosi P, Gélisse R, et al. Hypoalbuminemia in elderly patients with acute diastolic heart failure. J Am Coll Cardiol 2003; 42:712.</a></li><li><a class="nounderline abstract_t">Uthamalingam S, Kandala J, Daley M, et al. Serum albumin and mortality in acutely decompensated heart failure. Am Heart J 2010; 160:1149.</a></li><li><a class="nounderline abstract_t">Bonilla-Palomas JL, Gámez-López AL, Moreno-Conde M, et al. Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. J Card Fail 2014; 20:350.</a></li><li><a class="nounderline abstract_t">González-Pacheco H, Amezcua-Guerra LM, Sandoval J, et al. Prognostic Implications of Serum Albumin Levels in Patients With Acute Coronary Syndromes. Am J Cardiol 2017; 119:951.</a></li><li><a class="nounderline abstract_t">Taylor AE. Capillary fluid filtration. Starling forces and lymph flow. Circ Res 1981; 49:557.</a></li></ol></div><div id="topicVersionRevision">Topic 3456 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319101" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Causes and treatment of oedema in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31060086" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathogenesis of Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382065" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice. Acute pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794816" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Uremic lung: new insights into a forgotten condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/463915" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The value of edema fluid protein measurement in patients with pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10793167" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037521" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Causes of mortality in patients with the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588761" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An unusual cause of unilateral pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735767" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unilateral pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/619405" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Unilateral pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805429" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31596497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unilateral pulmonary oedema after minimally invasive and robotically assisted mitral valve surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10559099" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27645688" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788208" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841896" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837838" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients--relation to tidal volume size and development of acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359292" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Assessment of acute lung injury/acute respiratory distress syndrome using B-type brain natriuretic peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Decision support tool for differential diagnosis of Acute Respiratory Distress Syndrome (ARDS) vs Cardiogenic Pulmonary Edema (CPE): a prospective validation and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28828358" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556667" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diffuse Alveolar Hemorrhage in Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24862147" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Supportive transfusion therapy in cancer patients with acquired defects of hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31518182" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14601715" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute lung injury and the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30157406" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2100979" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33169217" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fluid administration and monitoring in ARDS: which management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714767" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of two fluid-management strategies in acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334568" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacological agents for adults with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24835849" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rosuvastatin for sepsis-associated acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33952601" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Awake prone positioning for hypoxaemic respiratory failure: past, COVID-19 and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27179988" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23339640" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-frequency oscillatory ventilation on shaky ground.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815658" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263687" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mortality rates for patients with acute lung injury/ARDS have decreased over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903337" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470008" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Functional disability 5 years after acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31718695" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758234" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical practice: Acute high-altitude illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143879" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute high-altitude sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31117074" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neurological Perspectives of Neurogenic Pulmonary Edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26066018" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neurogenic Pulmonary Edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21335128" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21268727" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic thromboembolic pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33121723" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27112656" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30854316" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role and management of extracorporeal life support after surgery of chronic thromboembolic pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818568" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reexpansion pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816309" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk factors for the development of reexpansion pulmonary edema in patients with spontaneous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25276359" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An analysis of and new risk factors for reexpansion pulmonary edema following spontaneous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15515513" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Complications following ultrasound-guided thoracocentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576360" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ultrasound-guided thoracentesis: is it a safer method?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954079" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Large-volume thoracentesis and the risk of reexpansion pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958824" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Reexpansion pulmonary edema after large-volume thoracentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20489660" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reexpansion pulmonary edema: computed tomography findings in 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12554036" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Reexpansion pulmonary edema: a case report and review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499336" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Complications following symptom-limited thoracentesis using suction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499336" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Complications following symptom-limited thoracentesis using suction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33682423" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182316" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pulmonary Complications of Opioid Overdose Treated With Naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636734" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effects of opioids on the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808097" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulmonary edema in fatal heroin overdose: immunohistological investigations with IgE, collagen IV and laminin - no increase of defects of alveolar-capillary membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713145" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Heroin-related noncardiogenic pulmonary edema : a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25174015" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599624" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Post-mortem whole body computed tomography of opioid (heroin and methadone) fatalities: frequent findings and comparison to autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7283290" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Salicylate-induced pulmonary edema. Clinical features and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297545" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Current management of salicylate-induced pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27531848" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Use of continuous renal replacement therapy in salicylate toxicity: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588066" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24993686" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute respiratory distress attributed to sirolimus in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592294" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26916490" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Acute Pulmonary Embolism: With an Emphasis on an Interventional Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520269" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pleural effusions due to pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3847304" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pleural effusion associated with pulmonary embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298456" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Analysis of pleural effusions in acute pulmonary embolism: radiological and pleural fluid data from 230 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941549" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hantavirus pulmonary syndrome: the new American hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498487" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690092" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A novel coronavirus associated with severe acute respiratory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534190" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932607" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hypoalbuminemia in elderly patients with acute diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146671" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Serum albumin and mortality in acutely decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24486927" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28160977" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prognostic Implications of Serum Albumin Levels in Patients With Acute Coronary Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7020975" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Capillary fluid filtration. Starling forces and lymph flow.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
